Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.43 |
| ▸ | TK1 | P04183 | 3/20 | 0.42 |
| ▸ | BCHE | P06276 | 4/20 | 0.41 |
| ▸ | TOP2A | P11388 | 6/20 | 0.40 |
| ▸ | TYMS | P04818 | 2/20 | 0.38 |
| ▸ | TK2 | O00142 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27914580 | 1.00 | RNASE1 (0.43) | RNASE1TK1BCHETOP2ATYMS | |
| SCHEMBL1335300 | 1.00 | RNASE1 (0.43) | RNASE1TK1BCHETOP2ATYMS | |
| SCHEMBL23734352 | 0.90 | TOP2A (0.49) | RNASE1TK1BCHETOP2ATYMS | |
| SCHEMBL31074282 | 0.85 | TK1 (0.42) | RNASE1TK1BCHETOP2ATYMS | |
| SCHEMBL20810641 | 0.85 | TK1 (0.58) | TK1BCHETYMS | |
| SCHEMBL22977550 | 0.85 | TK1 (0.58) | TK1BCHETYMS | |
| SCHEMBL29760775 | 0.82 | TOP2A (0.58) | RNASE1TK1TOP2ATK2 | |
| SCHEMBL4578740 | 0.82 | TOP2A (0.58) | RNASE1TK1TOP2ATK2 | |
| SCHEMBL4578745 | 0.82 | TOP2A (0.58) | RNASE1TK1TOP2ATK2 | |
| SCHEMBL26571122 | 0.81 | RNASE1 (0.52) | RNASE1TK1TOP2ATK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102971335-B | Reversibly terminating primer extension reagents | 史蒂芬·阿尔伯特·本纳 | 2016-06-29 | — | — | CN | disclosed |
| US-8212020-B2 | Reagents for reversibly terminating primer extension | BENNER STEVEN ALBERT (US) | 2012-07-03 | — | — | US | disclosed |
| US-20110275124-A1 | Reagents for reversibly terminating primer extension | BENNER STEVEN A | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275124-A1 | Reagents for reversibly terminating primer extension | RNGTT, POLRMT, DNTT | RNASE1 135/4885TK1 76/4885BCHE 2560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.